Experts discuss practical treatment selection for renal cell carcinoma across risk groups

A recent educational segment featured Dr. Elizabeth Plimack together with Dr. Sundhar Ramalingam and Dr. Yasser Ged discussing treatment choices for renal cell carcinoma.

The conversation centered on how clinicians tailor first-line therapy according to the International Metastatic RCC Database Consortium (IMDC) risk categories, highlighting practical considerations for each group.

The segment is part of a larger series that covers topics such as first-line trial evolution, combination strategies, non-clear cell disease, and real-world application, aiming to help practitioners translate trial data into practice.